Effects of therapy using a helicase–primase inhibitor (HPI) in mice infected with deliberate mixtures of wild-type HSV-1 and an HPI-resistant UL5 mutant

Point mutations in the HSV-1 UL5 (helicase) gene confer resistance to helicase–primase inhibitors (HPIs), e.g. BAY 57-1293. Such mutations normally occur at a frequency of ≤10 −6 PFU. However, individual HSV-1 laboratory strains and some clinical isolates contained resistance mutations (e.g. UL5: Ly...

Ausführliche Beschreibung